Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Levis, Mark J

Class:IdPerson:9683352
_displayNameLevis, Mark J
_timestamp2020-04-14 14:51:30
created[InstanceEdit:9683356] Rothfels, Karen, 2020-04-14
firstnameMark J
initialMJ
surnameLevis
(author)[LiteratureReference:9683353] Targeting FLT3 mutations in AML: review of current knowledge and evidence
[LiteratureReference:9699393] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
[LiteratureReference:9702959] FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia
[Change default viewing format]
No pathways have been reviewed or authored by Levis, Mark J (9683352)